Self-tests for COVID-19: what is the evidence? A living systematic review and meta-analysis (2020-2023)

Apoorva Anand^{1,2}, Fiorella Vialard^{1,2,3}, Aliasgar Esmail⁴, Faiz Ahmad Khan^{1,3}, Patrick

O'Byrne⁵, Jean-Pierre Routy^{2,3}, Keertan Dheda⁴, Nitika Pant Pai^{1,2,3*}

¹Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada

²Infectious Diseases and Immunity in Global Health, Research Institute of McGill University Health Centre, Montreal, Quebec, Canada

³Faculty of Medicine, McGill University, Montreal, Quebec, Canada

⁴Centre for Lung Infection and Immunity, Division of Pulmonology, UCT Lung Institute and Department of Medicine, University of Cape Town, Cape Town, Western Cape, South Africa

⁵Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada

*Corresponding author:

E-mail: <u>nitika.pai@mcgill.ca</u> (NPP)

Short title: COVID-19 self-tests: a living systematic review and meta-analysis

1 Abstract

2	COVID-19 self-testing strategy (COVIDST) can rapidly identify symptomatic and
3	asymptomatic SARS-CoV-2-infected individuals and their contacts, potentially reducing
4	transmission. In this living systematic review, we evaluated the evidence for real-world
5	COVIDST performance. Two independent reviewers searched six databases (PubMed, Embase,
6	Web of Science, World Health Organization database, Cochrane COVID-19 registry, Europe
7	PMC) for the period April 1st, 2020, to January 18th, 2023. Data on studies evaluating COVIDST
8	against laboratory-based conventional testing and reported on diagnostic accuracy, feasibility,
9	acceptability, impact, and qualitative outcomes were abstracted. Bivariate random effects meta-
10	analyses of COVIDST accuracy were performed (n=14). Subgroup analyses (by sampling site,
11	symptomatic/asymptomatic infection, supervised/unsupervised strategy, with/without digital
12	supports) were conducted. Data from 70 included studies, conducted across 25 countries with a
13	median sample size of 817 (range: 28-784,707) were pooled. Specificity was high overall,
14	irrespective of subgroups (98.37-99.71%). Highest sensitivities were reported for: a)
15	symptomatic individuals (73.91%, 95%CI: 68.41-78.75%; n=9), b) mid-turbinate nasal samples
16	(77.79%, 95%CI: 56.03-90.59%; n=14), c) supervised strategy (86.67%, 95%CI: 59.64-96.62%;
17	n=13), and d) presence of digital interventions (70.15%, 95%CI: 50.18-84.63%; n=14).
18	Sensitivity was lower in asymptomatic populations (40.18%, 95% CI: 21.52-62.20%; n=4), due
19	to errors in test conduct and absence of supervision or a digital support. We found no difference
20	in COVIDST sensitivity between delta and omicron pre-dominant period. Digital supports
21	increased confidence in COVIDST reporting and interpretation (n=16). Overall acceptability was
22	91.0-98.7% (n=2) with lower acceptability reported for daily self-testing (39.5-51.1%).

- 23 Feasibility was 69.0-100.0% (n=5) with lower feasibility (35.9-64.6%) for serial self-testing.
- 24 COVIDST decreased closures in school, workplace, and social events (n=4). COVIDST is an
- 25 effective rapid screening strategy for home-, workplace- or school-based screening, for
- 26 symptomatic persons, and for preventing transmission during outbreaks. This data is useful for
- 27 updating COVIDST policy. Our review demonstrates that COVIDST has paved the way for the
- 28 introduction of self-tests, worldwide.

29 Introduction

30	COVID-19 cases are rapidly declining due to extensive vaccine coverage but clustering is
31	reported in select subgroups (i.e., unvaccinated and immune suppressed individuals) [1]. A shift
32	towards greater use of self-tests was observed towards the end of 2021. Widespread availability
33	of rapid self-test kits, either through public distribution systems, or through private pharmacies,
34	convenience stores, or online websites, empowered individuals to exercise autonomy in
35	managing their exposures and guiding their actions.
36	COVID-19 self-testing strategies (COVIDST), are those where individuals collect their
37	own samples, test themselves, interpret results, and use them to inform their actions post-self-
38	test. COVIDST has particularly made the case for expanded access in the global north. However,
39	it has greater value in areas with limited resources, in the setting of expensive/absent laboratory-
40	based conventional testing, and in outbreaks [2].
41	COVIDST conducted with rapid diagnostic tests (RDTs) can detect active COVID-19
42	infection in a rapid turnaround time (TAT), thereby offering a convenient, user-friendly
43	alternative to conventional reverse transcription polymerase chain reaction (RT-PCR) tests.
44	Conventional tests require long wait times and longer TATs with increased risk of COVID-19
45	exposure [3, 4]. Alternatively, COVIDST can reduce dependence on healthcare workers (HCW)
46	and reduce exposure in healthcare settings by allowing self-testing in safe, private spaces. Rapid
47	identification of symptomatic SARS-CoV-2-infected individuals prevents exposure in
48	community contacts and allows a timely knowledge of infection status, prompting informed
49	action plans. Action plan initiation can greatly reduce transmission and mitigate burden on
50	healthcare systems.

51	A Cochrane systematic review which assessed diagnostic accuracy of HCW-performed
52	RDTs reported an average sensitivity of 72% in symptomatic individuals and 58% in
53	asymptomatic individuals. However, researchers did not report outcomes beyond accuracy where
54	RDTs were used as self-tests [5]. The World Health Organization (WHO) guidelines on
55	COVIDST implementation released in early 2022 provide evidence on diagnostic accuracy [6].
56	An explosion of literature in 2022-2023 on real world performance underscores the need for a
57	comprehensive, living review of evidence beyond diagnostic performance.
58	The overarching goal of this living systematic review is to update existing policies, fill
59	evidence gaps, and provide guidance to enhance quality of tests and reporting systems in line
60	with WHO guidelines, and to guide future outbreaks of COVID-19.
61	The review aims to: a) explore variability in COVIDST diagnostic performance across
62	the spectrum of its use in a meta-analysis; b) summarize feasibility, acceptability, accessibility,
63	and public health impact of COVIDST; and c) document qualitative outcomes.
64	

65 Methods

We registered our protocol on PROSPERO (CRD42022314799) [7]. No patients, study
participants, or members of the public were involved in the design, conduct, or reporting of this
review.

69

70 Data sources and searches

71 Two independent reviewers (AA, FV) searched five electronic databases (Pubmed,
72 Embase, Web of Science, WHO database, and Cochrane COVID-19 registry) from April 1st,

- 73 2020, to January 18th, 2023, for peer-reviewed journal articles and conference abstracts. Grey
- 74 literature was searched through the Europe PMC pre-prints database (Fig 1). No restrictions were
- placed on language or publication year. We will update the review until August 1st, 2023.
- 76 Fig 1. PRISMA Flow diagram
- 77

78 Search string:

- 79 (COVID-19* OR covid* OR "SARS-CoV-2*") AND
- 80 ("Self-test*" OR "Self test*" OR "Self-screen*" OR "Self screen*" OR "home test*" OR "at
- 81 *home test*" OR "at-home test*")* (S1 Box).

82

83 Study selection

84 All studies (observational and experimental) evaluating COVIDST strategies were included. Modelling studies, commentaries, narratives, opinion pieces, review articles, and case 85 reports were excluded. Titles, abstracts, and full texts were independently screened for eligibility 86 87 based on pre-specified inclusion and exclusion criteria. Disagreements were resolved by 88 discussion and consultation with a senior reviewer (NPP) (Fig 1). 89 Data extraction and quality assessment 90 Data across all global geographic regions (low-, middle-, and high-income) were 91 independently abstracted. Intervention included molecular/antigen/antibody COVID-19 self-92

93 tests. Comparators included conventional RT-PCR testing by HCWs or other trained

94 professionals.

95	Primary outcome was diagnostic accuracy (i.e., sensitivity, specificity, and diagnostic
96	odds ratio [DOR]) [8]. Authors were contacted for data when not completely available.
97	Secondary outcome data on feasibility, acceptability, new infections detection,
98	preferences, and impact were abstracted and reported with summary estimates of proportions and
99	95% confidence intervals (CI) [8, 9]. Tertiary outcomes included qualitative measures such as
100	motivations, facilitators, and barriers. (S1 Table).
101	Quality Assessment of Diagnostic Accuracy Studies Tool 2 (QUADAS-2) was used to
102	assess risk of bias in diagnostic accuracy studies (DAS). Newcastle-Ottawa Scale (NOS) was
103	used for observational studies and Cochrane Risk of Bias Tool 2 (RoB2) for randomized
104	controlled trials (RCTs) [10-14].
105	
106	Data synthesis and meta-analyses

107 Diagnostic accuracy was explored in forest plots and heterogeneity was evaluated using i^2 108 metric. Using bivariate random-effects meta-analysis, variability in COVIDST performance 109 across populations was explored.

Subgroup analyses were conducted for: 1) Symptom status (asymptomatic versus
symptomatic individuals); 2) Strategy (supervised versus unsupervised testing strategy); 3) Site
of self-sampling specimens (anterior nasal versus mid-turbinate nasal versus combined nasaloropharyngeal versus saliva); 4) Digital support presence versus absence (i.e., websites,
smartphone applications, test readers, other online tools).
All analyses were conducted in R statistical software using mada and meta packages [15,
16].

117

118 **Results**

119 Study selection

- 120 Seventy studies (peer-reviewed=65, preprints=5) were included. Nine of these studies
- 121 were retrieved through bibliographic search (Fig 1).

122

123 Study characteristics

124 Of seventy studies conducted across 25 countries, 63 (90.0%) were conducted in high-

income countries (HICs) and eight (11.43%) in low- and middle-income countries (LMICs) [17].

126 Three studies were conducted in multiple countries [3, 18, 19]. Sample sizes ranged from 28 to

127 784,707 with a median sample size of 817. (S2 Table)

128 COVIDST strategies included mass screening (n=32), targeted screening (i.e., school,

129 college, university, nursing home, sports club) (n=28), and healthcare facility-based screening

130 (n=8).

131 Populations studied were: 1) general population members (n=39), 2) teachers, parents,

school, and university students (n=11), 3) healthcare and laboratory staff (n=10), 4) hospital

patients (n=5), 5) drug addiction treatment patients (n=1), 6) office employees (n=1), 7) nursing

- homes residents and staff (n=1), 8) music festival attendees (n=1), and 9) Black, Indigenous, and
- 135 People of Colour (BIPOC) community (n=1).

Sampling sites used were anterior and mid-turbinate nasal, salivary, nasopharyngeal, andoropharyngeal.

138 Studies were	conducted in asympto	matic (n=17), sym	ptomatic (n=3), or both
------------------	----------------------	-------------------	-------------------------

- asymptomatic and symptomatic (n=27) individuals.
- 140 Thirty-four studies reported unsupervised/at-home self-testing strategy, ten studies
- 141 evaluated supervised self-testing strategy, and two studies evaluated both. In supervised self-
- 142 testing, the entire procedure was observed by trained HCWs or research staff, who may/may not
- 143 intervene if it was incorrectly conducted or if assistance was required. In unsupervised

144 COVIDST, unobserved testing was performed in testing centres or at-home.

145 Digital supports for COVIDST (n=20 studies) included websites, smartphone

146 applications, and video-based instructions. Of these, nine studies reported digital components

147 that aided in improving self-testing accuracy.

148

149 Synthesized results for primary outcome (diagnostic accuracy)

150 Diagnostic performance of COVIDST was evaluated in two ways: A) narrative synthesis151 and B) meta-analysis.

First, we reported sensitivity/specificity by test devices, symptom onset, covid variants, and cycle threshold (CT) values, for which we were unable to meta-analyze due to paucity of data and studies (Narrative synthesis, Primary outcome). We reported 95% confidence intervals (95% CIs) where available. Subsequently, we generated a forest plot from pooled sensitivity and specificity (n=14). For subgroups where data was available, we conducted a meta-analysis with pooled data (Meta-analysis results, Primary outcome).

158

159 Narrative synthesis

160 Diagnostic accuracy results from individual studies were summarized across test devices

161 (n=14), by symptom onset (n=4), by CT value (n=3), and by variants (n=2). We could not

- 162 perform a meta-analysis for these categories.
- 163 Four studies reported on diagnostic performance across 15 different COVIDST devices
- 164 (S3 Table). Of these, four test devices reported WHO-recommended sensitivities above 80%:
- 165 Boson SARS-CoV-2 antigen test card (98.18%, 95% CI: 96.74%–99.62%), Biosynex in
- symptomatic populations (93.8%; 95% CI: 79.3%–98.4%), Biosynex in asymptomatic
- 167 populations (83.3%; 95% CI: 73.4%-90.0%), Standard Q by SD Biosensor (82.50%, 95% CI:
- 168 68.1%–91.3% and 94.38%, 95% CI: 87.54%-98.60%), and MP Bio (83.01%, 95% CI: 78.8%-
- 169 86.7%). Specificities were above 91% for all devices. [20-26].
- 170 Four studies reported accuracies by day of symptom onset. Two studies reported
- sensitivities of 99.18% one day prior to symptom onset, 98.77-100% on first 2 days, and 100%
- from day 2 to 7 of symptom onset [20, 25]. Conversely, a community-based study reported
- sensitivities of 23% within 0-1 days and 66.67% within 2-4 days of symptom onset [23]. Finally,
- another study reported a sensitivity of 73% when self-test was conducted within 0-5 days of

symptom onset as compared to 22% when conducted after 5 days [27].

Three studies reported on self-test performance by cycle threshold (CT) values. Low CT values of positive RT-PCR results indicated a high viral load in swab samples. RT-PCR and selftest results were compared; CT value was checked for each self-test result. One study detected 100% of infections with COVIDST when CT values were below 20, 92% when CT values were between 20-30, and 33.33% when CT values were above 30 [20]. COVIDST in 2 studies detected: 1) symptomatic cases when mean CT value was 23.1 (IQR: 19.5–30.0) and median CT

value was 14 (IQR: 12.0-18.0); 2) asymptomatic cases when mean CT value was 28.2 (IQR:
25.0–33.0) [23, 28].

Two studies compared COVIDST performance in delta versus omicron variant infected populations. In one study, sensitivities decreased from 87.0% in the delta period to 80.9% in the omicron period [26]. Conversely, in another study, same-day sensitivity of self-tests was higher (22.1%, 95%CI: 15.5-28.8%) in omicron period versus 15.5% (95%CI: 6.2-24.8%) in delta period [29].

189

190 Meta-analyses results

191 Fourteen studies reported data on accuracy [19-26, 30-35]. First, we pooled sensitivities

and specificities to create forest plots (S1 Fig A and B). Following this, we assessed

193 heterogeneity and conducted subgroup analyses; results are summarized below.

194 Our forest plots reported a point estimate for pooled sensitivity (n=14) of 75.0% (95%CI:

195 59.0%-86.0%) (S1 Fig A). Sensitivities varied from 25% to 98%. Random effects model

heterogeneity i^2 statistic was high at 97%. Point estimate for pooled specificity (n=14) was 100%

197 (95%CI: 99.0%-100.0%) (S1 Fig B). Specificities varied from 97% to 100%. Random effects

198 model heterogeneity i^2 statistic was high at 94%.

We conducted subgroup analyses to explore this heterogeneity further. Summary receiver
 operating characteristic (SROC) curves were plotted for all subgroups (S2 Fig A-D). Pooled
 sensitivities, specificities, and DORs estimates are provided in Table 1.

202

203 Table 1. Meta-analyses of COVIDST diagnostic accuracy

Sr No	Category	Sub-groups	Sensitivity	95% CI	Specificity	95% CI	DOR	95% CI
		Anterior nasal	63.8	46.68- 78.00	99.29	98.73- 99.60	263	123- 497
		Mid-turbinate nasal	77.79	56.03- 90.59	98.62	94.35- 99.67	291	84.1- 741
1	Specific sampling site	Saliva	39.1	18.45- 64.57	99.32	97.60- 99.81	98.8	55.50- 163.00
		Combined nasal- oropharyngeal	69.69	58.96- 78.62	99.18	97.84- 99.69	303	124- 625
		Symptomatic	73.91	68.41- 78.75	98.37	97.47- 98.95	175	108- 270
2	Symptomatic status	Asymptomatic	40.18	21.52- 62.20	99.71	99.29- 99.88	249	104- 508
							_	
		Supervised	86.67	59.64- 96.62	99.39	97.04- 99.88	1530	200- 5670
3	Testing method	Unsupervised	60.69	50.31- 70.18	99.13	98.60- 99.47	181	116- 269
	Digital Intervention	Present	70.15	50.08- 84.63	99.39	97.99- 99.82	409	193.00- 764.00
4		Absent	65.69	54.06- 75.70	99.17	98.66- 99.49	237	135- 387

205

Significance	P-value
***	[0, 0.001)
**	(0.001, 0.01)
*	(0.01, 0.05)
	(0.05, 0.1)
	(0.1, 1)
Reference	e variable

206

207

In subgroup analyses by sampling sites (n=14), highest sensitivity was reported in samples from mid-turbinate sampling (77.79%, 95%CI: 56.03%-90.59%), followed by combined nasal-oropharyngeal sampling (69.69%, 95%CI: 58.96%-78.62%), and anterior nasal sampling

231	Test positivity (new infections detected)
230	Synthesized results for secondary outcomes
229	
228	digital supports. DOR was higher (409.00) with digital supports than without them (237.00).
227	(65.69%, 95%CI: 54.06%-75.70%). Specificity was 99% irrespective of presence/absence of
226	Sensitivity was higher with digital supports (70.15%, 95%CI: 50.08%-84.63%) than without
225	Fourteen studies analyzed COVIDST performance with/without digital supports.
224	versus in unsupervised (181.00) COVIDST.
223	Specificity was high at 99% irrespective of strategy. DOR was higher in supervised (1530.00)
222	96.62%) versus a sensitivity of 60.69% (95%CI: 50.31%-70.18%) in unsupervised strategy.
221	COVIDST. Supervised strategy reported a higher sensitivity of 86.67% (95%CI: 59.64%-
220	Thirteen out of fourteen studies evaluated performance of supervised and unsupervised
219	asymptomatic versus 175 in symptomatic populations.
218	Specificity was above 97% irrespective of symptomatic status. DOR was high at 249 for
217	statistically significant) versus 40.18% (95%CI: 21.52%-62.20%) for asymptomatic populations.
216	of symptoms. For symptomatic populations, sensitivity was 73.91% (95%CI: 68.41%-78.75%,
215	Nine out of fourteen studies reported diagnostic accuracy data based on presence/absence
214	lowest for saliva specimens (98.80).
213	sampling site. DOR was highest for combined nasal-oropharyngeal specimens (303.00) and
212	sampling (39.10%, 95%CI: 18.45%-64.57%). Specificity was above 98% irrespective of
211	(63.80%, 95%CI: 46.68%-78.0%, statistically significant). Sensitivity was lowest with salivary

232	Across twenty studies, new infections detected by COVIDST varied from 0.02% to 27%
233	[22, 25, 27, 28, 31, 36-48]. In two other studies, test positivity varied from 12% to 83.3% during
234	the delta wave and 41.7% to 87.2% during the omicron wave [29, 49]. Point prevalence for at-
235	home COVIDST was 3.7% compared to 5.5% for testing by HCWs .[47].
236	
237	Acceptability and willingness to use
238	Thirteen studies reported an overall high acceptability and willingness to use COVIDST.
239	COVIDST acceptability was high (91%-98.7%) in two studies, with higher acceptability in
240	females (73.91%) versus males (60.09%) reported in another study [50-52]. Acceptability was
241	lower (39.48%-51.1%) for daily self-testing [38, 40, 52]. Hesitancy to test (33.8%) and concerns
242	about test accuracy (1%) made people decline COVIDST [40].
243	Across three studies in different populations, COVIDST uptake was 97% in school
244	children, 92.5% in children with medical problems, and 45.2% in a mass self-testing study [41,
245	43, 53]. Across seven studies, willingness to use nasal self-tests ranged from 77% to 95.8% [2,
246	54-59].
247	
248	Feasibility and usability
249	Eighteen studies reported high COVIDST feasibility and ease of use. Usability threshold,
250	defined as the ability to correctly conduct all critical self-test steps, was higher with digital
251	supports.
252	An overall high feasibility was reported (69.6%-100%) across five studies [23, 40, 45, 60,
253	61]. In three studies, feasibility was lower for serial-testing COVIDST (35.9%-64.6%) [41, 50,
	14

254 62]. The average completion rate was 4.3 self-tests over 4.8 weeks in another serial-testing study255 [62].

256 Across seven studies, participants found COVIDST easy to use (81%-100%) [22, 30, 34, 257 45, 59, 63, 64]. Specifically, two studies reported a high ease of conducting at-home self-tests (95.7%), ease of reading self-test results (92%), and ease of remembering to test regularly (96%) 258 259 [22, 38]. 260 Across four studies, confidence in reporting test results and testing abilities was high 261 (70%-98%) [30, 34, 38, 65]. Regular COVIDST by dentists improved perception of safety while 262 treating patients by 49% [66]. Usability threshold was assessed in three studies. A high usability threshold was reported 263 from Malawi (82.4%-90.4%) and Zimbabwe (65.4%-70.6%) [2]. In Germany, usability was 264 265 61.2%, while in France, it increased from 99.1% to 100% with video supports [23, 67]. 266

267 **Preference**

Across six studies, preference for COVIDST varied from 29% to 87.9% [32, 45, 51, 64, 65, 67]. Overall, COVIDST preference was higher among white people, urban populations, political right, individuals with a college degree, and healthcare workers, as compared to ethnic minorities, rural populations, political left, individuals with a lower education, and working in other occupations [32, 51, 59, 63, 68, 69]. 94% of participants preferred throat swab-based selftest and 90% preferred saliva-based self-tests [55]. In another study, 95.4% participants preferred over-the-counter vending machines to obtain self-test kits [70].

275

276 Impact outcomes

277 Impact outcomes were evaluated in eighteen studies. In four studies, COVIDST reduced 278 closures in different institutions and of public events. Regular COVIDST in a peri-urban primary 279 school resulted in fewer school closures and decreased secondary infections in one study [71]. In 280 another, daily mass COVIDST resulted in 8,292 workday savings of essential workers [41]. 281 Self-tests were also used as daily testing tools in high exposure HCWs, allowing them to 282 quarantine immediately in case of a positive result and prevent infection transmission [28]. In 283 addition to healthcare settings, COVIDST facilitated the safe working of co-working health 284 laboratory sites in a pandemic setting [31]. Furthermore, pre-event COVIDST allowed attendees 285 to safely enjoy music concerts, wherein 87% of self-testers perceived a lower risk of contracting 286 COVID-19 at the concert [72]. Three studies reported a higher TAT with COVIDST compared to conventional testing. 287 288 In one study, TAT of 15-30 minutes for COVIDST versus 24-48 hours for RT-PCR was reported 289 [22]. Antigen self-tests had a mean TAT of 8.1 minutes (standard deviation: 1.3) [23]. In another 290 study, self-tests identified 23.5% of infections within 24 hours, and 54.9% of infections in the 291 next 48 hours, prior to obtaining RT-PCR results. 292 Impact of COVIDST on action plans (n=7) and self-test result notification (n=4) was reported. In four studies, willingness to notify close contacts and relevant authorities was 80%-293 294 97.6% [2, 52, 54, 57]. In two studies, a high proportion of respondents (80.78%-98.32%) were 295 willing to seek post-test counselling following a positive result [52, 57]. In three studies, 93%-296 100% testers expressed willingness to self-isolate following a positive test result [2, 57, 73]. 297 Although only 49% of HCWs believed that self-testers would self-isolate themselves following a 298 positive result, they opined that self-testers would take steps to reduce infection transmission [2].

299	Across two studies, 54%-78.3% of participants preferred validating initial COVIDST
300	results through repeat testing [23, 54, 57]. In three studies, 70.1%-92.6% self-testers sought
301	confirmatory RT-PCR testing [39, 41, 54]. Children aged 5-11 years and 12-18 years with a
302	positive unsupervised self-test result were more likely to obtain a confirmatory PCR test
303	compared to supervised testers (Odds ratio=3.48, 95%CI: 2.68-4.52 and Odds ratio=2.16,
304	95%CI: 1.86-2.50, respectively) [36].
305	
306	Qualitative outcomes
307	Qualitative outcomes such as motivations, facilitators, and barriers were assessed in 26
308	studies.
309	Motivators to self-test were protecting one's health and reducing infection transmission to
310	close contacts, partaking in daily activities and physically accessing services, workplace safety,
311	travelling, dining outside, and attending large gatherings [45, 54, 67, 72, 74, 75]. Higher
312	motivations to test were linked to a higher socioeconomic status (SES) and ability to acquire test
313	kits [45, 69, 72, 74].
314	COVIDST facilitators assessed in twelve studies included self-test training prior to use,
315	non-intrusive and ease of testing at-home, increased sense of safety, detailed self-test
316	instructions, faster turnaround time, and instructional videos [23, 28, 32, 57, 61, 62, 67, 69, 71,
317	76-80].
318	Across nine studies, COVIDST barriers included high costs, low trust in accuracy and
319	reliability, anxiety, hesitation in self-test conduct, uncomfortable self-swabbing procedures,
320	difficulty following instructions and interpreting faint positive test lines, lack of perceived
321	benefit, and inequitable access to COVIDST [21-23, 53, 62, 79, 81-83].

322

323 Self-testing with digital supports

324	Across fifteen studies, COVIDST digital supports used were: online platforms (n=6),
325	app-based COVIDST (n=6), video-based instructions (n=5), and online supervised COVIDST
326	(n=6) [22-24, 32, 34, 38-40, 45, 46, 49-51, 59-62, 65, 72, 84].
327	In four studies, app-assisted COVIDST allowed 98%-100% of participants to
328	successfully interpret their test results, [38, 50, 60, 84]. while video-taped self-testing process
329	increased participants' confidence (76%) in COVIDST results [72].
330	In another four studies, uploading a test result picture or reporting test results online was
331	a requirement that allowed HCWs to monitor and isolate positive cases [40, 49, 51, 60, 65].
332	In a mass COVIDST study, digital supports increased result notification in 75% of self-
333	testers [84]. A self-testing and COVID-19 exposure notification app utilized such self-reported
334	COVIDST results to reduce risk of infection in non-infected app users. [48, 49]. However,
335	unincentivized and voluntary reporting with a digital assistant in one mass COVIDST study was
336	low (4.6%) [84]. Also, digital reporting varied by test result; 3.2% reported positive test results
337	and 1.8% reported negative test results [60]. One study reported that federal COVID-19 statistics
338	did not include 42.8% of participants with a positive self-test result [48].
339	

340 **Risk of bias assessment**

To assess any publication bias in studies included in the meta-analysis, a funnel plot was
plotted (S3 Fig). A low risk of bias was estimated using Deek's method (p-value of 0.79).

343	Using the QUADAS-2 tool (n=14), we found low risk of bias across all categories except
344	for reference standards (unclear risk, n=6) (S4 Table A). Cohort studies (n=13) had an average
345	risk of bias in the comparability category (1-star, n=7) (S4 Table B). Similarly, cross-sectional
346	studies (n=41) also had an average risk of bias in the comparability category (1-stars, n=12) (S4
347	Table C). One case-control study had an overall poor risk of bias score across all categories.
348	Finally, RoB2 tool was used for one qualitative RCT study wherein low risk for all domains was
349	observed except for the selection of reported result domain.

350

351 **Discussion**

This review demonstrates that COVIDST strategies are effective in screening SARS-CoV-2 infections. Self-testing has a faster TAT compared to conventional testing, can be used in outbreak settings, prevent institutional closures, and reduce infection transmission in various settings.

356

357 Diagnostic accuracy and caveats

358 Our meta-analyses demonstrated very high specificity and above average sensitivity of359 COVIDST strategies.

360 Specificity for COVIDST (across all tests) was consistently above 98% regardless of

361 different subgroups. Specificity is computed by calculating all true negatives (TN)/true negatives

- 362 (TN) and false positives (FP). If the specificity is high, and the person is asymptomatic, we can
- 363 be certain that the false positives are low.

In contrast, sensitivity for COVIDST varied across subgroups; highest sensitivities were reported for: a) mid-turbinate nasal specimens (77.79%, 95% CI: 56.03%-90.59%), b) tests conduct in supervised settings (86.67%, 95% CI: 59.64%-96.62%), c) symptomatic individuals (73.91%, 95% CI: 68.41%-78.75%), and d) digital COVIDST (70.15%, 95% CI: 50.08%-84.63%).

369 Sensitivity is computed by reporting true positives (TP)/true positives (TP) plus false 370 negatives (FN). With that, if false negatives increase, sensitivity falls. In symptomatic 371 individuals, highest sensitivities were reported for the first 5 days of symptom onset. In contrast, 372 for asymptomatic individuals, sensitivities were consistently low (40.18%). Interpreting 373 sensitivity and specificity is tricky at the population level, therefore simple messaging is very important for populations seeking to implement or use these self-tests. Our results show lower 374 375 COVIDST sensitivity were due to unclear instructions for use, inadequate pre-test training, 376 incorrect test conduct, non-adherence to instructions, and difficulties in interpreting faint positive 377 test lines. To improve COVIDST performance, diagnostic companies need to design self-test kits 378 with consideration for low-literacy and senior populations. Self-test instructions for conduct and 379 interpretation must be detailed, comprehensive, and provided in layman terms. In areas with high 380 digital literacy and data connectivity, video-based instructions and virtual pre-test training 381 sessions can be provided.

Additionally, sensitivities were higher when CT value was lower or equal to 25. This is an important feature to note while sharing information on self-tests. Variance in sensitivity based on CT values show that self-tests can detect infections most accurately with peak viral loads and contagiousness. These findings highlight that the value of self-testing lies in the rapid identification and prompt isolation of highly contagious individuals compared to RT-PCR

387	positive tests. A median PCR positivity period of 22-33 days gives a positive test result in the
388	presence of viral particles that persist even after resolution of infection.
389	Comparatively, most false negative self-test results occur when individuals are outside
390	the transmissibility window [85]. If a COVIDST result is negative but an RT-PCR test result is
391	positive, it is likely that the individual is not very infectious and may not pose a public health
392	threat [85].
393	As for test devices used, some devices performed consistently as per WHO – for
394	example, the Boson SARS-CoV-2 antigen test card, Biosynex, Standard Q at-home test, and MP
395	Bio – while others did not (Please refer to Appendix table 3). Regarding strains, in the two
396	studies that evaluated COVIDST performance by variants, we noted no difference in sensitivities
397	for either the delta or the omicron strain pre-dominant periods. This is reassuring for future
398	strains of the virus.

399

400 Secondary and tertiary outcomes

401 COVIDST screening strategies offer benefits in pandemic settings, when accessibility to 402 laboratory testing is very limited, and timely test results are of the essence. Our results show that 403 COVIDST strategies consistently reported a rapid TAT, were overall highly acceptable, highly 404 feasible, and convenient to populations around the world. Their usability index was at 100% with 405 additional digital supports. These supports included video-based or app-based instructions, 406 highlighting the potential of digital COVIDST.

407 Our results are consistent with the interim guidance on self-testing provided by WHO,408 which found self-testing acceptable, feasible, and easy to use by laymen; however, our results are

409 updated and include data that can serve WHO to adapt their guidance. These results were also 410 very similar to the proven benefits that have been demonstrated with HIV self-testing [86]. Despite established COVID-19 nucleic acid amplification testing (NAAT) surveillance 411 412 systems in many countries, COVIDST became an important screening and decision-making tool for individuals during the peak of the pandemic [87]. Our results show that regular COVIDST 413 414 was instrumental in impacting onward transmission that stemmed from the pandemic. This 415 impact was demonstrated in reducing school closures, resuming in-person education, and 416 allowed attendees to safely attend social events. Healthcare workers were able to treat patients 417 while monitoring themselves, thereby reducing the risk of nosocomial infections. 418 Serial testing during the pandemic, especially in high exposure jobs, allowed essential workers to resume work without fear of losing pay and laboratories were able to remain 419 420 operational. Participants were willing to report results, adhere to self-isolation guidelines, and 421 seek confirmatory testing following a positive self-test result. Periodic self-testing reduced 422 anxiety and created an environment of safety and reassurance when resuming normal activities. 423 Overall, participants were motivated to use COVIDST strategies to know their infection status, resume daily activities, protect their loved ones, and exercise caution while attending 424 large gatherings. Motivations and preference for COVIDST over lab-based testing increased with 425 426 a higher SES and in urban areas. Inequitable access to self-tests in ethnic minorities with a lower SES was observed. This 427 428 alludes to inequity in distribution of self-tests that was largely restricted to those with resources.

This pattern could be changed for future pandemics by reducing the unit price of self-tests andpublic procurement of tests for large scale use.

431 Evidence on COVIDST parallels the vast evidence that has accumulated for HIVST.

Both viruses have paved the way for a greater use of self-testing solutions to know serostatus,
and by increasing accessibility offered by these solutions during the pandemic, have made selftests a common household name. This strategy holds promise for many infectious pathogens and
pandemics.

436

437 Strengths and limitations

To our knowledge, ours is the first comprehensive and updated systematic review and

439 meta-analysis on COVIDST. Although WHO released COVIDST guidelines, data on diagnostic

440 accuracy then were scarce, so meta-analyses could not be performed. Additionally, these

guidelines were based on studies published before February 2022 while our updated review

442 contains recent studies (2023) that complement these results.

Our review is based on observational data. With a few RCTs underway, new data will
soon become available [88, 89]. Most of the data are from HICs (n=63), making our results
difficult to generalize to LMICs. Finally, no studies were reported with highly accurate

446 molecular rapid COVIDST strategies [90].

447

448 Implication for product development and research

Publicly distributed self-tests can guarantee widespread accessibility but should be
implemented with evidence-based strategies to improve test conduct and result interpretation.
Checks for counterfeit test kits are necessary and regulating the sales of COVIDST kits can help
improve public confidence in self-testing.

453 Public health sector and not-for-profit organizations along with healthcare facilities and
454 pharmacies can increase access to self-tests by free-of-cost, widespread distribution of kits in
455 urban and rural areas.

A strong and connected reporting system must be implemented by local authorities to avoid underestimating the true burden of infections. Future research can explore COVIDST diagnostic performance with digitally connected platforms, apps, test readers, and systems to report message notification and linkage to care. Data from clinical trials are needed to fill the gaps in evidence from LMICs.

461

462 **Conclusion**

463 Self-testing complements conventional testing in the pandemic setting with its speed and 464 efficiency when time is of the essence. Our review demonstrates that COVIDST is a convenient 465 and effective strategy for screening infections when used by the general population.

In symptomatic populations, in supervised settings with guided instructions, and with the addition of digital supports, self-tests improved in their performance. COVIDST had a high usability threshold, impacted institutional closures, and reported results notification where reporting systems were in place. However, data from LMICs were limited due to scarcity of selftesting.

471 Digital COVIDST is promising, and additional data will help improve accuracy and trust.
472 Our results can aid policymakers, government bodies, and healthcare systems in updating their
473 policies, and organizations aimed at integrating triple self-testing strategies in their health

474	ecosystems. COVIDST can alleviate the impact of the COVID-19 pandemic across all global
475	settings and their widespread availability will help address global health inequities.
476	Both HIVST and COVIDST have demonstrated the impact that self-tests can have in
477	empowering lay individuals to know their serostatus and in preventing forward transmission.
478	This approach holds promise for the many self-tests for related pathogens (HCV, HBV, Syphilis,
479	and MPox), and use of this tool can aid in ending future waves of these pandemics.
480	
481	Acknowledgements
482	The authors would like to thank Olivia Vaikla for her assistance with proofreading and

483 formatting the manuscript.

484

485 Authors' contributions

AA and NPP designed, drafted, and reviewed the initial manuscript while the remaining
authors (FV, FK, AE, POB, JPR, KD) provided critique on subsequent drafts. Search strategy
was developed and executed by AA, FV, and NPP. Data abstraction and quality assessment were
performed by AA and FV. All authors (AA, FV, FK, AE, POB, JPR, KD, NPP) have reviewed
and approved the final written manuscript.

491

492 Data availability

493 All data relevant to the study are included in the article or uploaded as supplementary494 information.

495 **References**

496 1. COVID-19 Situation Reports: The World Health Organization; 2022. Available
 497 from: <u>https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-</u>
 498 19---9-november-2022.

499 2. Use of SARS-CoV-2 antigen rapid diagnostic tests for COVID19 self-testing

INTERIM GUIDANCE- Web Annex B.: The World Health Organization; 2022. Available
 from: <u>https://apps.who.int/iris/bitstream/handle/10665/352345/WHO-2019-nCoV-Ag-</u>
 RDTs-Self-testing-Web-annex-B-2022.1-eng.pdf.

503 3. Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-504 testing: The World Health Organization; 2022. Available from:

505 https://www.who.int/publications/i/item/WHO-2019-nCoV-Ag-RDTs-Self testing-2022.1.

4. Procop GW, Kadkhoda K, Rhoads DD, Gordon SG, Reddy AJ. Home testing for COVID-19: Benefits and limitations. Cleve Clin J Med. 2021. doi:

508 10.3949/ccjm.88a.ccc071.

509 5. Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, et al. Rapid, 510 point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.

511 Cochrane Database Syst Rev. 2021;3(3):CD013705-CD. doi:

512 10.1002/14651858.CD013705.pub2. PubMed PMID: 33760236.

513 6. Web Annex A. GRADE table: Should COVID-19 self-testing,

using SARS-CoV-2 Ag-RDTs, be offered as an additional

515 approach? : The World Health Organization; 2022. Available from:

516 https://apps.who.int/iris/bitstream/handle/10665/352344/WHO-2019-nCoV-Ag-RDTs-

517 <u>Self-testing-Web-annex-A-2022.1-eng.pdf</u>.

Apoorva A, Nitika PP, Fiorella V, Faiz AK, Ali E, Patrick OB, et al. Diagnostic
 performance, feasibility, and real-world evaluation of COVID-19 self-tests: A living
 systematic review & meta-analysis protocol [Protocol]. PROSPERO-International
 prospective register of systematic reviews; 2022.

Pant Pai N, Sharma J, Shivkumar S, Pillay S, Vadnais C, Joseph L, et al.
 Supervised and unsupervised self-testing for HIV in high- and low-risk populations: a
 systematic review. PLoS Med. 2013;10(4):e1001414-e. Epub 2013/04/02. doi:
 10.1371/journal.pmed.1001414. PubMed PMID: 23565066.

Pant Pai N, Chiavegatti T, Vijh R, Karatzas N, Daher J, Smallwood M, et al.
 Measures and Metrics for Feasibility of Proof-of-Concept Studies With Human
 Immunodeficiency Virus Rapid Point-of-Care Technologies: The Evidence and the
 Framework. Point Care. (1533-029X (Print)). doi: 10.1097/POC.00000000000147.

Penny FW, Anne W S R, Marie E W, Susan M, Jonathan J D, Johannes B R, et
al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.
Ann Intern, Med. (1539-3704 (Electronic)). doi: 10.7326/0003-4819-155-8-20111018000009.

534 11. G A W, B S, D OC, J P, V W, M L, et al. The Newcastle-Ottawa Scale (NOS) for
535 assessing the quality of nonrandomised studies in meta-analyses 2011. Available from:
536 <u>http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</u>.

537 12. RoB 2: A revised Cochrane risk-of-bias tool for randomized trials: Cochrane

538 Methods. Available from: <u>https://methods.cochrane.org/bias/resources/rob-2-revised-</u> 539 cochrane-risk-bias-tool-randomized-

trials#:~:text=Version%202%20of%20the%20Cochrane,design%2C%20conduct%2C%
 20and%20reporting.

542 13. Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, et al.

543 Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-544 Analysis. PLoS one. 2016;11(1):e0147601. doi: 10.1371/journal.pone.0147601.

Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, et al.
Panethnic differences in blood pressure in europe: a systematic review and metaanalysis- S1: NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE

548 (adapted for cross sectional studies). PLoS one. 2016. doi:549 10.1371/journal.pone.0147601.

550 15. Philipp D, Heinz H, Bernardo S-P. Meta-Analysis of Diagnostic Accuracy with

mada: The Comprehensive R Archive Network. Available from: <u>https://cran.r-</u>
 <u>project.org/web/packages/mada/vignettes/mada.pdf</u>.

Schwarzer G. General Package for Meta-Analysis: The Comprehensive R
 Archive Network. Available from: <u>https://cran.r-project.org/web/packages/meta/meta.pdf</u>.

The World by Income and Region: The World Bank; 2021. Available from:
 https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html.

55818.Boulliat C, Bilong CV, Dussart C, Massoubre B. Use of self-tests and rapid559diagnostic tests: Survey of dispensing pharmacists in the Auvergne-Rhone-Alpes

560 region. Ann Pharm Fr. 2021;79(5):547-57. doi:

561 <u>http://dx.doi.org/10.1016/j.pharma.2021.01.011</u>. PubMed PMID: 2011983076.

562 19. García-Fiñana M, Hughes DM, Cheyne CP, Burnside G, Stockbridge M, Fowler
563 TA, et al. Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the
564 Liverpool asymptomatic testing pilot: population based cohort study. BMJ.
565 2021;374:n1637. doi: 10.1136/bmj.n1637.

- 566 20. Kim S, Choi W. Performance of standard q covid-19 ag home test to detect sars-567 cov-2 within five days of disease onset. Clin Chem Lab Med. 2021;59(SUPPL 1):S606. 568 doi: http://dx.doi.org/10.1515/cclm-2021-5027. PubMed PMID: 636561836.
- 569 21. Lindner AK, Nikolai O, Rohardt C, Kausch F, Wintel M, Gertler M, et al.
- 570 Diagnostic accuracy and feasibility of patient self-testing with a SARS-CoV-2 antigen-
- 571 detecting rapid test. J Clin Virol. 2021;141 (no pagination). doi:
- 572 <u>http://dx.doi.org/10.1016/j.jcv.2021.104874</u>. PubMed PMID: 2013057417.

573 22. Schuit E, Venekamp R, Veldhuijzen I, van den Bijllaardt W, Pas S, Stohr J, et al.

574 Accuracy and usability of saliva and nasal rapid antigen self-testing for detection of

575 SARS-CoV-2 infection in the general population: a head-to-head comparison. medRxiv.

576 2021. doi: 10.1101/2021.12.08.21267452. PubMed PMID: PPR431858.

577 23. Tonen-Wolyec S, Dupont R, Awaida N, Batina-Agasa S, Hayette MP, Belec L.
578 Evaluation of the practicability of biosynex antigen self-test covid-19 ag+ for the
579 detection of sars-cov-2 nucleocapsid protein from self-collected nasal mid-turbinate
580 secretions in the general public in france. Diagnostics. 2021;11(12) (no pagination). doi:
581 http://dx.doi.org/10.3390/diagnostics11122217. PubMed PMID: 2014709998.

Zwart VF, van der Moeren N, Stohr JJJM, Feltkamp MCW, Bentvelsen RG,
Diederen BMW, et al. Performance of Various Lateral Flow SARS-CoV-2 Antigen Self
Testing Methods in Healthcare Workers: a Multicenter Study. medRxiv. 2022. doi:
10.1101/2022.01.28.22269783. PubMed PMID: PPR447982.

Leventopoulos M, Michou V, Papadimitropoulos M, Vourva E, Manias NG,
Kavvadas HP, et al. Evaluation of the Boson rapid Ag test vs RT-PCR for use as a selftesting platform. Diagn Microbiol Infect Dis. 2022;104(3):115786. Epub 20220729. doi:
10.1016/j.diagmicrobio.2022.115786. PubMed PMID: 35998553; PubMed Central
PMCID: PMCPMC9335347.

Schuit E, Venekamp RP, Hooft L, Veldhuijzen IK, van den Bijllaardt W, Pas SD,
et al. Diagnostic accuracy of covid-19 rapid antigen tests with unsupervised selfsampling in people with symptoms in the omicron period: cross sectional study. Bmj.
2022;378:e071215. Epub 20220914. doi: 10.1136/bmj-2022-071215. PubMed PMID:
36104069; PubMed Central PMCID: PMCPMC9471225.

596 27. Bae S, Park H, Kim JY, Park S, Lim SY, Bae JY, et al. Daily, self-test rapid
597 antigen test to assess SARS-CoV-2 viability in de-isolation of patients with COVID-19.
598 Front Med (Lausanne). 2022;9:922431. Epub 20221019. doi:

599 10.3389/fmed.2022.922431. PubMed PMID: 36341265; PubMed Central PMCID: 600 PMCPMC9627621.

28. Downs LO, Eyre DW, O'Donnell D, Jeffery K. Home-based SARS-CoV-2 lateral
flow antigen testing in hospital workers. J Infect. (1532-2742 (Electronic)). doi:
10.1016/j.jinf.2021.01.008. PubMed Central PMCID: PMCPMC7870106.

Soni A, Herbert C, Filippaios A, Broach J, Colubri A, Fahey N, et al. Comparison
of Rapid Antigen Tests' Performance between Delta (B.1.61.7; AY.X) and Omicron
(B.1.1.529; BA1) Variants of SARS-CoV-2: Secondary Analysis from a Serial Home
Self-Testing Study. J Intern Med. 2022. doi: <u>https://doi.org/10.7326/M22-0760</u>.

So. Frediani JK, Levy JM, Rao A, Bassit L, Figueroa J, Vos MB, et al.
Multidisciplinary assessment of the Abbott BinaxNOW SARS-CoV-2 point-of-care
antigen test in the context of emerging viral variants and self-administration. Sci Rep.
2021;11(1):14604. Epub 20210716. doi: 10.1038/s41598-021-94055-1. PubMed PMID:
34272449; PubMed Central PMCID: PMCPMC8285474.

31. Harmon A, Chang C, Salcedo N, Sena B, Herrera BB, Bosch I, et al. Validation of
an At-Home Direct Antigen Rapid Test for COVID-19. JAMA Netw Open.
2021;4(8):e2126931. Epub 20210802. doi: 10.1001/jamanetworkopen.2021.26931.
PubMed PMID: 34448871; PubMed Central PMCID: PMCPMC8397931.

Møller IJB, Utke AR, Ryesgaard UK, Østergaard LJ, Jespersen S. Diagnostic
Performance, User Acceptability, and Safety of Unsupervised SARS-CoV-2 Rapid
Antigen Detecting Tests Performed at Home. Int J Infect Dis. 2021. doi:
10.1016/j.ijid.2022.01.019

33. Tim P, UK C-LFOT. COVID-19: Rapid Antigen detection for SARS-CoV-2 by
lateral flow assay: a national systematic evaluation for mass-testing. medRxiv.
2021:2021.01.13.21249563. doi: <u>https://doi.org/10.1101/2021.01.13.21249563</u>.

34. Stohr J, Zwart VF, Goderski G, Meijer A, Nagel-Imming CRS, Kluytmans-van den
Bergh MFQ, et al. Self-testing for the detection of SARS-CoV-2 infection with rapid
antigen tests for people with suspected COVID-19 in the community. Clin Microbiol
Infect. 2021. Epub 20210804. doi: 10.1016/j.cmi.2021.07.039. PubMed PMID:
34363945; PubMed Central PMCID: PMCPMC8336990.

35. Venekamp RP, Schuit E, Hooft L, Veldhuijzen IK, van den Bijllaardt W, Pas SD,
et al. Diagnostic accuracy of SARS-CoV-2 rapid antigen self-tests in asymptomatic
individuals in the omicron period: a cross-sectional study. Clin Microbiol Infect. 2022.

Epub 20221113. doi: 10.1016/j.cmi.2022.11.004. PubMed PMID: 36379401; PubMed
Central PMCID: PMCPMC9659357.

36. Hughes DM, Bird SM, Cheyne CP, Ashton M, Campbell MC, García-Fiñana M, et
al. Rapid antigen testing in COVID-19 management for school-aged children: an
observational study in Cheshire and Merseyside, UK. J Public Health (Oxf). 2022. Epub
20220204. doi: 10.1093/pubmed/fdac003. PubMed PMID: 35137216.

638 37. Cassuto NG, Gravier A, Colin M, Theillay A, Pires-Roteira D, Pallay S, et al.
639 Evaluation of a SARS-CoV-2 antigen-detecting rapid diagnostic test as a self-test:
640 Diagnostic performance and usability. J Med Virol. 2021;93(12):6686-92. Epub
641 20210826. doi: 10.1002/jmv.27249. PubMed PMID: 34331707; PubMed Central
642 PMCID: PMCPMC8426870.

38. Hirst JA, Logan M, Fanshawe TR, Mwandigha L, Wanat M, Vicary C, et al.
Feasibility and Acceptability of Community Coronavirus Disease 2019 Testing
Strategies (FACTS) in a University Setting. Open Forum Infect Dis. 2021;8(12):ofab495.
Epub 20211004. doi: 10.1093/ofid/ofab495. PubMed PMID: 34904117; PubMed Central
PMCID: PMCPMC8515264.

Sumb G, Heskin J, Randell P, Mughal N, Moore LS, Jones R, et al. Real-world
evaluation of COVID-19 lateral flow device (LFD) mass-testing in healthcare workers at
a London hospital; a prospective cohort analysis. J Infect. 2021;83(4):452-7. doi:
http://dx.doi.org/10.1016/j.jinf.2021.07.038. PubMed PMID: 2014190661.

40. Love N, Ready D, Turner C, Yardley L, Rubin GJ, Hopkins S, et al. The
acceptability of testing contacts of confirmed COVID-19 cases using serial, selfadministered lateral flow devices as an alternative to self-isolation. J Med Microbiol.
2021. doi: <u>https://doi.org/10.1099/jmm.0.001567</u>.

41. Institute of Population Health UoL. Covid-SMART Asymptomatic Testing

- 657 Pilot in Liverpool City Region:
- 658 Quantitative Evaluation 2022. Available from:

https://www.liverpool.ac.uk/media/livacuk/coronavirus/Liverpool_City_Region_Covid_S
 MART_Evaluation-Feb.pdf.

42. Qasmieh SA, Robertson MM, Teasdale CA, Kulkarni SG, Nash D. Estimating the

Period Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) Infection During the Omicron (BA.1) Surge in New York City (NYC), 1 January to 16

64 March 2022. Clin Infect Dis. doi: 10.1093/cid/ciac644. PubMed PMID:

665 WOS:000848015700001.

43. Coller RJ, Kelly MM, Howell KD, Warner G, Butteris SM, Ehlenbach ML, et al. InHome COVID-19 Testing for Children with Medical Complexity: Feasibility and
Association With School Attendance and Safety Perceptions. Am J Public Health.
2022:e1-e5. Epub 20220915. doi: 10.2105/ajph.2022.306971. PubMed PMID:
36108256.

44. Papenburg J, Campbell JR, Caya C, Dion C, Corsini R, Cheng MP, et al.
Adequacy of Serial Self-performed SARS-CoV-2 Rapid Antigen Detection Testing for
Longitudinal Mass Screening in the Workplace. JAMA Netw Open. 2022;5(5):e2210559.
Epub 20220502. doi: 10.1001/jamanetworkopen.2022.10559. PubMed PMID:
35522284; PubMed Central PMCID: PMCPMC9077488.

45. Agustí C, Martínez-Riveros H, González V, Fernández-Rivas G, Díaz Y,
Montoro-Fernandez M, et al. Feasibility of an online antigen self-testing strategy for
SARS-CoV-2 addressed to health care and education professionals in Catalonia
(Spain). The TESTA'T- COVID Project. PLoS One. 2022;17(9):e0275006. Epub
20220927. doi: 10.1371/journal.pone.0275006. PubMed PMID: 36166432; PubMed
Central PMCID: PMCPMC9514624.

682 46. O'Byrne P, Orser L, Musten A, Ho N, Haines M, Lindsay J. Delivering COVID
683 self-tests through GetaKit.ca: Creating testing access during a pandemic. Public Health
684 Nurs. 2023. Epub 20230110. doi: 10.1111/phn.13168. PubMed PMID: 36625331.

47. Qasmieh SA, Robertson MM, Rane MS, Shen Y, Zimba R, Picchio CA, et al. The
Importance of Incorporating At-Home Testing Into SARS-CoV-2 Point Prevalence
Estimates: Findings From a US National Cohort, February 2022. JMIR Public Health
Surveill. 2022;8(12):e38196. Epub 20221227. doi: 10.2196/38196. PubMed PMID:
36240020; PubMed Central PMCID: PMCPMC9822564.

48. Stemler J, Salmanton-García J, Weise B, Többen C, Joisten C, Fleig J, et al. A
pilot surveillance report of SARS-CoV-2 rapid antigen test results among volunteers in
Germany, 1st week of July 2022. Infection. 2022:1-5. Epub 20221024. doi:
10.1007/s15010-022-01931-7. PubMed PMID: 36279033; PubMed Central PMCID:
PMCPMC9590393.

49. Daniore P, Nittas V, Ballouz T, Menges D, Moser A, Höglinger M, et al.
Performance of the Swiss Digital Contact-Tracing App Over Various SARS-CoV-2
Pandemic Waves: Repeated Cross-sectional Analyses. JMIR Public Health Surveill.
2022;8(11):e41004. Epub 20221111. doi: 10.2196/41004. PubMed PMID: 36219833;
PubMed Central PMCID: PMCPMC9700234.

50. Herbert C, Broach J, Heetderks W, Qashu F, Gibson L, Pretz C, et al. At-Home
Serial Testing Using Over-the-Counter SARS-CoV-2 Tests with a Digital Smartphone
App for Assistance: Findings of feasibility from a longitudinal cohort study. JMIR Form
Res. 2022. Epub 20220825. doi: 10.2196/35426. PubMed PMID: 36041004.

Martin AF, Denford S, Love N, Ready D, Oliver I, Amlôt R, et al. Engagement
with daily testing instead of self-isolating in contacts of confirmed cases of SARS-CoV2. BMC public health. 2021;21(1):1067. doi: 10.1186/s12889-021-11135-7.

52. Martinez-Perez GZ, Shilton S, Sarue M, Cesario H, Banerji A, Batheja D, et al.
Self-testing for SARS-CoV-2 in Sao Paulo, Brazil: results of a population-based values and attitudes survey. BMC Infect Dis. 2022;22(1). doi: 10.1186/s12879-022-07706-7.
PubMed PMID: WOS:000849202400001.

53. Marinos G, Lamprinos D, Georgakopoulos P, Oikonomou E, Zoumpoulis G,
Garmpis N, et al. Evaluation of Knowledge, Attitudes and Practices Related to SelfTesting Procedure against COVID-19 among Greek Students: A Pilot Study. Int J
Environ Res Public Health. 2022;19(8). Epub 20220410. doi: 10.3390/ijerph19084559.
PubMed PMID: 35457427; PubMed Central PMCID: PMCPMC9026819.

54. Betsch C, Sprengholz P, Siegers R, Eitze S, Korn L, Goldhahn L, et al. Empirical
evidence to understand the human factor for effective rapid testing against SARS-CoV2. Proc Natl Acad Sci USA. 2021;118(32). doi: 10.1073/pnas.2107179118. PubMed
PMID: 34362848; PubMed Central PMCID: PMCPMC8364214.

55. Mistler CB, Sullivan M, Wickersham JA, Copenhaver MM, Shrestha R. Clinical
and demographic differences in the willingness to use self-administered at-home
COVID-19 testing measures among persons with opioid use disorder. Subst Abus.
2022;43(1):708-12. doi: 10.1080/08897077.2021.2007511. PubMed PMID: 35100084.

56. Phillips G, Xu JY, Ruprecht MM, Costa D, Felt D, Wang XZ, et al. Associations
with COVID-19 Symptoms, Prevention Interest, and Testing Among Sexual and Gender
Minority Adults in a Diverse National Sample. Lgbt Health. 2021;8(5):322-9. doi:
10.1089/lgbt.2021.0002. PubMed PMID: WOS:000660215700001.

57. Thomas C, Shilton S, Thomas C, Batheja D, Goel S, Iye CM, et al. Values and
preferences of the general population in Indonesia in relation to COVID-19 self-testing:
A cross-sectional survey. Trop Med Int Health. 2022. doi: 10.1111/tmi.13748.

58. LeRouge C, Durneva P, Lyon V, Thompson M. Health Consumer Engagement,
Enablement, and Empowerment in Smartphone-Enabled Home-Based Diagnostic
Testing for Viral Infections: Mixed Methods Study. JMIR Mhealth Uhealth.
2022;10(6):e34685. Epub 20220630. doi: 10.2196/34685. PubMed PMID: 35771605;
PubMed Central PMCID: PMCPMC9284354.

59. Schilling J, Moeller FG, Peterson R, Beltz B, Joshi D, Gartner D, et al. Testing
the Acceptability and Usability of an Al-Enabled COVID-19 Diagnostic Tool Among
Diverse Adult Populations in the United States. Qual Manag Health Care.
2023;32(Suppl 1):S35-s44. doi: 10.1097/qmh.00000000000396. PubMed PMID:
36579707; PubMed Central PMCID: PMCPMC9811483.

60. Herbert C, Kheterpal V, Suvarna T, Broach J, Marquez JL, Gerber B, et al.
Design and Preliminary Findings of Adherence to the Self-Testing for Our Protection
From COVID-19 (STOP COVID-19) Risk-Based Testing Protocol: Prospective Digital
Study. JMIR Form Res. 2022;6(6):e38113. Epub 20220616. doi: 10.2196/38113.
PubMed PMID: 35649180; PubMed Central PMCID: PMCPMC9205422.

Hoehl S, Schenk B, Rudych O, Göttig S, Foppa I, Kohmer N, et al. HighFrequency Self-Testing by Schoolteachers for Sars-Cov-2 Using a Rapid Antigen Test–
Results of the Safe School Hesse study. Dtsch Arztebl Int. 2021;118(14):252-3. doi:
10.3238/arztebl.m2021.0187. PubMed PMID: 34114556; PubMed Central PMCID:
PMCPMC8283684.

62. Wanat M, Logan M, Hirst J, Vicary C, Lee JJ, Perera R, et al. Perceptions on
undertaking regular asymptomatic self-testing for COVID-19 using lateral flow tests: A
qualitative study of university students and staff. BMJ Open. 2021. doi:
http://dx.doi.org/10.1136/bmjopen-2021-053850.

Prazuck T, Gravier A, Pires-Roteira D, Theillay A, Pallay S, Colin M, et al.
Evaluation Of A New "All In One" Sars-Cov-2 Antigen-Detecting Rapid Diagnostic Test
And Self-Test: Diagnostic Performance And Usability On Child And Adult Population. J
Med Virol. 2021. doi: <u>https://doi.org/10.1002/jmv.27812</u>. PubMed PMID: PPR400123.

Prazuck T, Gravier A, Pires-Roteira D, Theillay A, Pallay S, Colin M, et al.
Evaluation of a new "all in one" SARS-CoV-2 antigen-detecting rapid diagnostic test and
self-test: Diagnostic performance and usability in child and adult populations. J Med
Virol. 2022;94(9):4097-106. Epub 20220525. doi: 10.1002/jmv.27812. PubMed PMID:
35474460; PubMed Central PMCID: PMCPMC9088384.

65. Denford S, Martin A, Love N, Ready D, Oliver I, Amlôt R, et al. Engagement with
daily testing instead of self-isolating in contacts of confirmed cases of SARS-CoV-2: A
qualitative analysis. Front Public Health. 2021. doi:

767 <u>https://doi.org/10.3389/fpubh.2021.714041</u>. PubMed PMID: PPR348017.

66. Coker MO, Subramanian G, Davidow A, Fredericks-Younger J, Gennaro ML,
Fine DH, et al. Impact of DHCWs' Safety Perception on Vaccine Acceptance and
Adoption of Risk Mitigation Strategies. JDR Clin Trans Res. 2022:23800844211071111.
Epub 20220222. doi: 10.1177/23800844211071111. PubMed PMID: 35191352.

Hajek A, Nedjad M, Kretzler B, König HH. [Use of and Attitudes toward Tests for
the Detection of SARS-CoV-2 and Corresponding Antibodies: Results of a Nationally
Representative Survey in Late Summer 2021]. Gesundheitswesen. 2023;85(1):26-35.
Epub 20220909. doi: 10.1055/a-1916-9895. PubMed PMID: 36084943.

Fishman J, Bien-Gund CH, Bisson GP, Baik Y. COVID-19 Self-Testing
 Preferences Linked to Political Perspectives: Social Determinants in the U.S. Pandemic.

Am J Prev Med. 2022. Epub 20221103. doi: 10.1016/j.amepre.2022.09.024. PubMed
PMID: 36411144; PubMed Central PMCID: PMCPMC9630136.

69. Wu F, Yuan Y, Li Y, Yin D, Lang B, Zhao Y, et al. The acceptance of SARS-CoV2 rapid antigen self-testing: A cross-sectional study in China. J Med Virol.
2023;95(1):e28227. Epub 20221025. doi: 10.1002/jmv.28227. PubMed PMID:
36241424.

784 70. Jairoun AA, Al Hemyari SS, Abdulla NM, Shahwan M, Bilal FHJ, Al-Tamimi SK,
r85 et al. Acceptability and Willingness of UAE Residents to Use OTC Vending Machines to
r86 Deliver Self-Testing Kits for COVID-19 and the Implications. J Multidiscip Healthc.
r87 2022;15:1759-70. doi: 10.2147/JMDH.S370441.

788 71. Wachinger J, Schirmer M, Tauber N, McMahon SA, Denkinger CM. Experiences
789 with opt-in, at-home screening for SARS-CoV-2 at a primary school in Germany: An
790 implementation study. BMJ Paediatr Open. 2021;5(1) (no pagination). doi:
791 <u>http://dx.doi.org/10.1136/bmjpo-2021-001262</u>. PubMed PMID: 636301367.

72. Dallera G, Alaa A, El-Osta A, Kreindler J, Harris M. Evaluating the feasibility and
acceptability of a safety protocol to mitigate SARS-CoV-2 transmission risks when
participating in full-capacity live mass events: a cross-sectional survey and interviewbased study. BMJ Open. 2022;12(12):e063838. Epub 20221223. doi: 10.1136/bmjopen2022-063838. PubMed PMID: 36564106; PubMed Central PMCID: PMCPMC9791109.

797 73. Woloshin S, Dewitt B, Krishnamurti T, Fischhoff B. Assessing How Consumers
798 Interpret and Act on Results From At-Home COVID-19 Self-test Kits A Randomized
799 Clinical Trial. JAMA Intern Med. doi: 10.1001/jamainternmed.2021.8075. PubMed
800 PMID: WOS:000750999100004.

801 74. Bien-Gund C, Dugosh K, Acri T, Brady K, Thirumurthy H, Fishman J, et al.
802 Factors Associated With US Public Motivation to Use and Distribute COVID-19 Self803 tests. JAMA Netw Open. 2021;4(1):e2034001. Epub 20210104. doi:
804 10.1001/jamanetworkopen.2020.34001. PubMed PMID: 33471114; PubMed Central
805 PMCID: PMCPMC7818126.

75. D'Agostino EM, Corbie G, Kibbe WA, Hornik CP, Richmond A, Dunston A, et al.
Increasing access and uptake of SARS-CoV-2 at-home tests using a communityengaged approach. Prev Med Rep. 2022;29:101967. Epub 20220830. doi:
10.1016/j.pmedr.2022.101967. PubMed PMID: 36061814; PubMed Central PMCID:
PMCPMC9424120.

76. Mouliou DS, Pantazopoulos I, Gourgoulianis KI. Societal Criticism towards
COVID-19: Assessing the Theory of Self-Diagnosis Contrasted to Medical Diagnosis.
Diagnostics (Basel). 2021;11(10). Epub 20210927. doi: 10.3390/diagnostics11101777.
PubMed PMID: 34679475; PubMed Central PMCID: PMCPMC8534791.

77. Thomas C, Shilton S, Thomas C, Iye CM, Martínez-Pérez G. COVID-19 selftesting, a way to "live side by side with the coronavirus": results from a qualitative study
in Indonesia. Res Sq. 2022. doi: 10.21203/rs.3.rs-1304157/v1. PubMed PMID:
PPR449862.

78. Willeit P, Bernar B, Zurl C, Al-Rawi M, Berghold A, Bernhard D, et al. Sensitivity
and specificity of the antigen-based anterior nasal self-testing programme for detecting
SARS-CoV-2 infection in schools, Austria, March 2021. Euro Surveill. 2021;26(34). doi:
10.2807/1560-7917.ES.2021.26.34.2100797. PubMed PMID: WOS:000689672400002.

79. Nwaozuru U, Obiezu-Umeh C, Diallo H, Graham D, Whembolua GL, Bourgeau
MJ, et al. Perceptions of COVID-19 self-testing and recommendations for
implementation and scale-up among Black/African Americans: implications for the
COVID-19 STEP project. Bmc public health. 2022;22(1). doi: 10.1186/s12889-02213619-6. PubMed PMID: WOS:000813757700001.

828 80. Rader B, Gertz A, Iuliano AD, Gilmer M, Wronski L, Astley CM, et al. Use of At829 Home COVID-19 Tests - United States, August 23, 2021-March 12, 2022. MMWR Morb
830 Mortal Wkly Rep. 2022;71(13):489-94. Epub 20220401. doi:

831 10.15585/mmwr.mm7113e1. PubMed PMID: 35358168; PubMed Central PMCID:
 832 PMCPMC8979595.

833 81. Goggolidou P, Hodges-Mameletzis I, Purewal S, Karakoula A, Warr T. Self834 Testing as an Invaluable Tool in Fighting the COVID-19 Pandemic. J Prim Care
835 Community Health. 2021;12:21501327211047782. doi: 10.1177/21501327211047782.
836 PubMed PMID: 34583571; PubMed Central PMCID: PMCPMC8485257.

82. Tulloch JSP, Micocci M, Buckle P, Lawrenson K, Kierkegaard P, McLister A, et
al. Enhanced lateral flow testing strategies in care homes are associated with poor
adherence and were insufficient to prevent COVID-19 outbreaks: results from a mixed
methods implementation study. Age Ageing. 2021;50(6):1868-75. doi:
10.1093/ageing/afab162.

842 83. Undelikwo V, Shilton S, Folayan MO, Alaba O, Reipold EI, Martínez-Pérez G.
843 COVID-19 self-testing in Nigeria: Stakeholders' opinions and perspective on its value for
844 case detection. medRxiv. 2022. doi: 10.1101/2022.01.28.22269743. PubMed PMID:
845 PPR447979.

846 84. Herbert C, Shi Q, Kheterpal V, Nowak C, Suvarna T, Durnan B, et al. Use of a
Digital Assistant to Report COVID-19 Rapid Antigen Self-test Results to Health
Departments in 6 US Communities. JAMA Netw Open. 2022;5(8):e2228885. Epub
20220801. doi: 10.1001/jamanetworkopen.2022.28885. PubMed PMID: 36018589;
PubMed Central PMCID: PMCPMC9419013.

85. Mina MJ, Peto TE, García-Fiñana M, Semple MG, Buchan IE. Clarifying the
evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19.
Lancet. 2021;397(10283):1425-7. doi: 10.1016/S0140-6736(21)00425-6.

86. McGuire M, de Waal A, Karellis A, Janssen R, Engel N, Sampath R, et al. HIV
self-testing with digital supports as the new paradigm: A systematic review of global
evidence (2010–2021). eClinicalMedicine. 2021;39. doi:
10.1016/j.eclinm.2021.101059. PubMed PMID: 101059.

87. Ritchey MD, Rosenblum HG, Del Guercio K, Humbard M, Santos S, Hall J, et al.
COVID-19 Self-Test Data: Challenges and Opportunities - United States, October 31,
2021-June 11, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(32):1005-10. Epub
20220812. doi: 10.15585/mmwr.mm7132a1. PubMed PMID: 35951486; PubMed
Central PMCID: PMCPMC9400539.

863 88. LLC N. COVID-19 Diagnostic Self-testing Using Virtual Point-of-care:

864 ClinicalTrails.gov; 2020. Available from:

865 <u>https://clinicaltrials.gov/ct2/show/NCT04348864</u>.

866 89. Robert Gross UoP. COVID-19 Self-Testing Through Rapid Network Distribution

- 867 (C-STRAND): ClinicalTrials.gov; 2021. Available from:
- 868 <u>https://clinicaltrials.gov/ct2/show/NCT04797858</u>.

869 90. Zahavi M, Rohana H, Azrad M, Shinberg B, Peretz A. Rapid SARS-CoV-2

870 Detection Using the Lucira[™] Check It COVID-19 Test Kit. Diagnostics (Basel).

871 2022;12(8). Epub 20220803. doi: 10.3390/diagnostics12081877. PubMed PMID:

872 36010227; PubMed Central PMCID: PMCPMC9406928.

873

874 Supporting information

- 875 S1 Box. Search String.
- 876 S1 Table. Outcomes Description.
- 877 S2 Table. Study Characteristics.
- 878 S3 Table. Diagnostic accuracy across test devices.
- 879 S1 Fig A and B. Forest Plot.
- 880 S2 Fig A-D. Comparison of summary receiver operating characteristic (SROC) curves.

- 881 S3 Fig. Funnel Plot of studies included in the meta-analysis (n=14).
- 882 S4 Table A-C. Risk of bias.



From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71. For more information, visit: http://www.prisma-statement.org/

Figure 1